| Nuvalent is a biopharmaceutical company focused on creating targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Co. focuses its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. In particular, Co. focuses on “clinically proven” kinase targets, or those for which therapies have been developed by others to target those kinases, and that such drugs have demonstrated sufficient clinical efficacy and safety data to be approved by FDA and are established and used in the clinical setting. We show 2 historical shares outstanding datapoints in our NUVL shares outstanding history coverage, used to compute NUVL market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NUVL market cap history over the course of time is important for investors
interested in comparing NUVL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NUVL versus a peer is one thing; comparing
NUVL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NUVL can fluctuate over the course of history.
With this page we aim to empower investors researching NUVL by allowing them to research the NUVL market cap history.